End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
315 SAR | 0.00% | +0.06% | +10.92% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 50.65 and 40.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.92% | 29.4B | C+ | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-31.75% | 11.77B | - | - | |
-1.42% | 11.72B | A- | ||
+27.44% | 11.71B | B- | ||
-3.97% | 11.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4013 Stock
- Ratings Dr. Sulaiman Al Habib Medical Services Group Company